Polar Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Polar Capital’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$8.98M	Buy	175,000 +25,000	+17%	+$1.22M	0.07%	185
2020 Q2	$8.96M	Sell	150,000 -466,261	-76%	-$24.9M	0.08%	180
2020 Q1	$25.4M	Buy	616,261 +140,777	+30%	+$7.82M	0.27%	110
2019 Q4	$29.6M	Buy	475,484 +169,506	+55%	+$8.06M	0.26%	126
2019 Q3	$10.4M	Buy	+305,978	New	+$9.06M	0.09%	191
2018 Q4	–	Sell	-805,004	Closed	-$31.2M	–	291
2018 Q3	$31.2M	Buy	805,004 +210,453	+35%	+$7.78M	0.27%	116
2018 Q2	$23.4K	Buy	594,551 +456,851	+332%	+$13.4M	0.14%	142
2018 Q1	$2.76M	Sell	137,700 -112,300	-45%	-$2.84M	0.03%	238
2017 Q4	$5.67M	Buy	+250,000	New	+$4.9M	0.06%	196

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Polar Capital's DCPH Position: Q3 2020 in Review

Polar Capital increased its Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) stake by 17% in Q3 2020, buying an estimated $1.22M and bringing the position to 175,000 shares worth $8.98M. The position accounts for 0.07% of the portfolio, ranked #185.

Polar Capital first reported a position in DCPH in Q4 2017 and has held it in 9 quarters since. The position peaked at $31.2M in Q3 2018. 161 funds tracked by Wall St. Rank hold DCPH as of Q3 2020.

Polar Capital held 175,000 shares of Deciphera Pharmaceuticals, Inc. Common Stock worth $8.98M as of Q3 2020.
Polar Capital bought 25,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $1.22M.
Deciphera Pharmaceuticals, Inc. Common Stock made up 0.07% of Polar Capital's portfolio in Q3 2020, its #185 holding.
Polar Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and has held it in 9 quarters since.
Polar Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $31.2M in Q3 2018.
161 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.